Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Tedatioxetine (Lu AA24530) is being developed by Lundbeck for the treatment of MDD. It is a multimodal antidepressant and preclinical studies have shown that it acts as a monoamine enhancer with reuptake inhibition at monoamine transporters, as well as a 5-HT3 and 5-HT2C receptor antagonist (Lundbeck, press release, July 2, 2009).
For Further Inquiries: http://www.radiantinsights.com/research/tedatioxetine-major-depressive-disorder-forecast-and-market-analysis-to-2023
Scope
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tedatioxetine including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tedatioxetine for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Request Free Sample Of This Study: http://www.radiantinsights.com/research/tedatioxetine-major-depressive-disorder-forecast-and-market-analysis-to-2023#tabs-4
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Tedatioxetine performance
- Obtain sales forecast for Tedatioxetine from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia).
About Us
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Website: Radiant Insights
Tedatioxetine (Lu AA24530) is being developed by Lundbeck for the treatment of MDD. It is a multimodal antidepressant and preclinical studies have shown that it acts as a monoamine enhancer with reuptake inhibition at monoamine transporters, as well as a 5-HT3 and 5-HT2C receptor antagonist (Lundbeck, press release, July 2, 2009).
For Further Inquiries: http://www.radiantinsights.com/research/tedatioxetine-major-depressive-disorder-forecast-and-market-analysis-to-2023
Scope
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tedatioxetine including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tedatioxetine for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Request Free Sample Of This Study: http://www.radiantinsights.com/research/tedatioxetine-major-depressive-disorder-forecast-and-market-analysis-to-2023#tabs-4
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Tedatioxetine performance
- Obtain sales forecast for Tedatioxetine from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia).
About Us
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Website: Radiant Insights
No comments:
Post a Comment